Biodesix shares plunge as Johnson Fistel launches investor probe
The Colorado office of law firm Johnson Fistel has launched an investigation on behalf of shareholders in the diagnostic company.
The Colorado office of law firm Johnson Fistel has launched an investigation on behalf of shareholders in the diagnostic company. Published 2026-11-11 by Falling Shares.
| By Falling Shares Intelligence, edited by Wung Thomas, Editor-in-Chief
Written by Falling Shares Intelligence, our automated newsroom, from the public sources listed below and live market data. Every figure is checked against that material before publication, but the story has not been reviewed by a human editor. Check the linked sources before relying on it, and report errors to info@fallingshares.com.
Shares in Biodesix fell sharply on Wednesday after Johnson Fistel’s Colorado office announced it was initiating an investigation on behalf of investors. The firm said it is looking into the company’s conduct and disclosures. No specific reason for the trading move was provided in the release.
Probe launched
Johnson Fistel stated in a GlobeNewswire release that its Colorado office is conducting an investigation into Biodesix. The firm said it is acting on behalf of investors who hold shares in the company. The announcement did not detail the specific concerns prompting the review.
The law firm said it is preserving evidence and reviewing documents related to the company. It invited other shareholders to contact the firm if they wish to participate in the investigation. The release did not specify a timeline for the probe’s completion.
Trading activity
Biodesix shares plunged in trading on Wednesday. The company is a provider of diagnostic tests for respiratory and infectious diseases. The stock has faced volatility in recent sessions as investors weigh regulatory and competitive pressures in the diagnostics sector.
None of the reports reviewed by Falling Shares gave a reason for the fall beyond the law firm’s announcement. The company did not issue a separate comment on the trading activity or the investigation at the time of publication.